BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12496063)

  • 1. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones.
    Jarred RA; Keikha M; Dowling C; McPherson SJ; Clare AM; Husband AJ; Pedersen JS; Frydenberg M; Risbridger GP
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1689-96. PubMed ID: 12496063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
    Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
    Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
    Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
    Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors.
    Grober ED; Tsihlias J; Jewett MA; Sweet JM; Evans AJ; Trachtenberg J; Robinette M; Nam RK
    Can J Urol; 2004 Feb; 11(1):2157-62. PubMed ID: 15003158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens.
    Poulos CK; Daggy JK; Cheng L
    Cancer; 2004 Aug; 101(3):527-32. PubMed ID: 15274065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
    Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD
    Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soy isoflavones in the treatment of prostate cancer.
    Hussain M; Banerjee M; Sarkar FH; Djuric Z; Pollak MN; Doerge D; Fontana J; Chinni S; Davis J; Forman J; Wood DP; Kucuk O
    Nutr Cancer; 2003; 47(2):111-7. PubMed ID: 15087261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.
    Varkarakis J; Pinggera GM; Sebe P; Berger A; Bartsch G; Horninger W
    Urology; 2004 Feb; 63(2):337-41. PubMed ID: 14972485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
    Cheng L; Koch MO; Juliar BE; Daggy JK; Foster RS; Bihrle R; Gardner TA
    J Clin Oncol; 2005 May; 23(13):2911-7. PubMed ID: 15860849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lycopene and soy isoflavones in the treatment of prostate cancer.
    Vaishampayan U; Hussain M; Banerjee M; Seren S; Sarkar FH; Fontana J; Forman JD; Cher ML; Powell I; Pontes JE; Kucuk O
    Nutr Cancer; 2007; 59(1):1-7. PubMed ID: 17927495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.